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In recent years, studies on the intracellular pathogen Francisella tularensis have greatly intensified, 
generating a wealth of new information on the interaction of this organism with the immune 
system. Here we review the basic elements of the innate and adaptive immune responses that 
contribute to protective immunity against Francisella species, with special emphasis on new data 
that has emerged in the last 5 years. Most studies have utilized the mouse model of infection, 
although there has been an expansion of work on human cells and other new animal models. 
In mice, basic immune parameters that operate in defense against other intracellular pathogen 
infections, such as interferon gamma, TNF-α, and reactive nitrogen intermediates, are central for 
control of Francisella infection. However, new important immune mediators have been revealed, 
including IL -17A, Toll-like receptor 2, and the inflammasome. Further, a variety of cell types in 
addition to macrophages are now recognized to support Francisella growth, including epithelial 
cells and dendritic cells. CD4+ and CD8+  T cells are clearly important for control of primary infection 
and vaccine-induced protection, but new  T cell subpopulations and the mechanisms employed by 
T cells are only beginning to be defined. A significant role for B cells and specific antibodies has 
been established, although their contribution varies greatly between bacterial strains of lower and 
higher virulence. Overall, recent data profile a pathogen that is adept at subverting host immune 
responses, but susceptible to many elements of the immune system’s antimicrobial arsenal.
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subsp. tularensis. These are now denoted A1a, A1b, and A2, in addi-
tion to Type B F. tularensis subsp. holarctica (Kugeler et al., 2009). 
Type A1 infections of humans tend to have a fulminant course with 
a high mortality rate, while Type A2 and Type B infections are rarely 
if ever lethal in humans (Staples et al., 2006; Kugeler et al., 2008). In 
studies in the U.S., differences in the attack rates of immunocom-
promised people for the various clades and subspecies have been 
described; 11 of 108 (10%) of Type B infections, 6 of 133 (6%) of 
A1 infections (both subtypes), and none of 68 A2 infections were 
diagnosed in people with an underlying immunocompromising 
condition, including medical conditions as diverse as end stage renal 
disease (Staples et al., 2006) and chronic granulomatous disease 
(CGD; Maranan et al., 1997). Nonetheless, the collective evidence 
suggests that the differences in virulence are largely due to intrin-
sic properties of the bacterial strains, and not directly related to 
host gender, susceptibility, genetics, or otherwise failed immune 
responses (Kugeler et al., 2009).
Because infection with Francisella is relatively infrequent in 
nature, informative examples of infection of people with primary 
or acquired immunodeficiencies subjects are rare. The handful of 
such cases prior to 2006, including infection of AIDS patients with 
reduced CD4+ T cell counts, has been reviewed elsewhere (Elkins 
et al., 2007), and thus will not be repeated here. More recently, 
an interesting case involving a 58-year-old man with refractory 
rheumatoid arthritis was described. The patient had been treated 
for about a year with methotrexate and an anti-TNF-α therapeutic 
(Humira®, adalimumab), when he presented with fever, a leg wound, 
enlarged lymph nodes, and eventually skin fistula. Tuberculosis was 
suspected initially; the lesion was surgically removed, and found 
IntroductIon and overvIew
Although Francisella tularensis is highly infectious and readily estab-
lishes disease at low doses in both humans and animals, it has long 
been recognized that human tularemia victims rarely if ever suffer 
a second episode of disease. The collective human infection expe-
rience therefore strongly suggests that natural infection engenders 
strong immune responses that are usually protective. The older lit-
erature contains a wealth of information on the pathogenesis and 
host response to Francisella drawn from studies in both humans 
and animals, including vaccination and challenge studies in humans 
that would be difficult if not impossible to replicate today. These 
studies have been recently reviewed extensively elsewhere (Conlan 
and Oyston, 2007; Elkins et al., 2007). But the history of studies 
on Francisella includes its development as a biowarfare pathogen 
(Dennis et al., 2001); as a result, the recent heightened interest in 
biodefense has produced a flood of new and exciting data, particu-
larly on respiratory infection and mucosal immune responses to this 
pathogen. The upsurge in studies is impressive: from 1900 to 2005, 
a search of PubMed for “Tularemia or Francisella” yielded a total of 
2921 references, but 858 citations from 2006 to 2011. Thus this review 
will focus primarily on developments in about the last 5 years.
Human in vivo Immune responses to Francisella 
InfectIon and vaccInatIon
Important components of Human Immune responses 
revealed by Francisella InfectIon
The most recent studies of the epidemiology of infection with 
F. tularensis subsp. tularensis, as well as subsp. holarctica, clearly 
indicate differences in virulence among clades of Type A F. tularensis 
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and nascent specific T cells. As a result, recent   biological assays being 
developed for diagnosis have been based on ex vivo stimulation of 
whole peripheral blood leukocytes with bacteria, followed by assess-
ment of IFN-γ secretion (Eliasson et al., 2008).
A curious, and still unexplained, feature of natural infection is 
the large expansion of phosphoantigen-responsive Vγ9/Vδ2 T cells 
in peripheral blood within the first 7 days after onset of symptoms 
in tularemia patients (Poquet et al., 1998). This intriguing phe-
nomenon, which can result in as many as 30% of all CD3+ cells 
in human peripheral blood being Vγ9/Vδ2 T cells, is discussed in 
more detail below.
Human Immune responses revealed by vaccInatIon agaInst 
Francisella
As noted above, and discussed in detail in another chapter in this 
issue, there is a long history of using various live attenuated strains 
of Francisella as vaccines, particularly in the former Soviet Union 
(Sändstrom, 1994). As a reference point for further discussion of 
immune responses generally, here we include a brief summary of 
human immune responses to the LVS strain. Usually administered 
by scarification, LVS has been studied in western countries and par-
ticularly in the U.S. These studies have mostly used investigational 
lots of LVS produced in the 1970s by the Department of the Army; 
more recently, LVS was re-derived from the original lots, and newly 
manufactured under modern GMP conditions (El Sahly et al., 2009). 
Microarray studies of gene changes in PBLs from five volunteers 
obtained between 1 and 14 days after vaccination with LVS indi-
cated a robust up-regulation of expression of pro-inflammatory 
mediators and genes involved in dendritic cell (DC) function, which 
peaked within 2 days (Fuller et al., 2006, 2007). Similar to natural 
infection, humans vaccinated with LVS develop specific IgM, IgA, 
and IgG antibodies in serum about 2 weeks after vaccination that 
persist for at least 1.5 years (Waag et al., 1995; El Sahly et al., 2009). 
However, as noted at the outset, anti-Francisella serum antibodies 
titers in vaccinated individuals have not been predictive of protec-
tion against virulent tularemia, and vaccination with killed bacteria 
(that elicit anti-Francisella antibodies but no detectable cell-medi-
ated immune responses) has provided little or no benefits in human 
studies (Francis and Felton, 1942; Foshay, 1950; Overholt et al., 1961; 
Saslaw et al., 1961a,b; Hambleton et al., 1974; Burke, 1977; Tärnvik, 
1989). In addition to serum antibodies, stimulated PBLs, or enriched 
CD4+ and CD8+ T cells, obtained from volunteers 2–4 weeks or more 
after LVS vaccination proliferated and produced typical Th1-type 
cytokines, especially IFN-γ, ex vivo (Waag et al., 1995; El Sahly et al., 
2009). In one study, the responding cells from both LVS vaccines 
and patients after natural infection were characterized as traditional 
CD4 and CD8 memory T cells, mostly with an effector memory 
phenotype (CD45RA−/+, CD62−; Salerno-Goncalves et al., 2009).
anImal models of Human ImmunIty to Francisella
Detailed consideration of animal models of Francisella infection is 
well beyond the scope of this article, and a comprehensive recent 
review is available elsewhere (Lyons and Wu, 2007). Nonetheless, 
because the bulk of data on immune responses is currently being 
generated using animal models of infection, here we include brief 
summaries of recent developments as they relate to modeling the 
immune responses of humans (for summary, see Table 1).
to  contain  necrotic  epithelioid  granulomas.  Surprisingly,  both 
  serology and PCR of a biopsied lymph node diagnosed F. tularen-
sis infection (Konstantinou et al., 2009). It is tempting to speculate 
that TNF-α deficiency, provided in this case by drug treatment, 
increased susceptibility to Francisella infection, similar to observa-
tions in animal models (Cowley et al., 2008) and in mycobacteria 
infections of humans (Gardam et al., 2003).
Of note, although only about 20 cases of human infection with 
F. philomiragia have been reported in the literature, disease caused 
by this species is usually associated with immune defects. These 
include corticosteroid treatment, CGD, and near-drowning epi-
sodes (Hollis et al., 1989; Sicherer et al., 1997). The association 
between Francisella and CGD, in which neutrophils fail to produce 
fully functional NADPH oxidase and thus reactive oxygen radicals, 
obviously suggests a role for these mediators in human resistance 
to infection.
The experimental literature now frequently refers to the immu-
nosuppressive nature of infection with virulent Francisella (the topic 
of another chapter in this issue), but naturally infected patients as 
well as vaccines eventually develop robust and readily measurable 
T and B cell responses to the bacterium. These responses have been 
studied for many years, particularly in regions such as Scandinavia 
which have appreciable amounts of disease. An outbreak of ulcero-
glandular tularemia in Sweden in 2003–2004 provided a unique 
opportunity to obtain peripheral blood cells from patients within 
days of infection, and perform large scale transcriptional profiling 
of human gene expression by microarray (Andersson et al., 2006a). 
Within 2–3 days, there was clear evidence for increased expression 
of genes regulated by interferon gamma (IFN-γ) and related to 
apoptosis, but also indications of down-regulation of many genes 
related to both innate and adaptive immune responses. Thus infec-
tion in humans may be characterized by both appropriate and 
subversive types of host reactions.
The major means to diagnose tularemia is still based on four-fold 
increase of serum antibodies to the bacterium between acute and 
convalescent sera. Robust specific IgM, IgG, and IgA serum antibod-
ies, much of them directed against Francisella lipopolysaccharide 
(LPS), can be detected roughly simultaneously about 6–10 days 
after the onset of symptoms, or about 2 weeks after infection. 
Antibody responses peak between 1 and 2 months after infection, 
and persist for about a decade before diminishing (Koskela and 
Salminen, 1985). Large scale efforts using 2-D gel blotting (Janovska 
et al., 2007) or protein chips with a library of Francisella proteins 
(Sundaresh et al., 2007), reacted with patient sera, are beginning to 
identify and catalog the bacterial proteins recognized. No obvious 
immunodominant B cell epitopes have been revealed, however, and 
as a result panels of antigens have been proposed for diagnostic 
purposes (Sundaresh et al., 2007).
Within about 2 weeks after infection, ex vivo production of typical 
Th1-type cytokines such as IFN-γ, TNF-α, and IL-2 by CD4
+ and CD8+ 
T cells is readily detectable in human peripheral blood lymphocytes 
(PBLs) obtained from tularemia patients (Koskela and Herva, 1980; 
Surcel et al., 1991). Unlike antibody responses, however, human CD4+ 
and CD8+ T cell PBL responses persist for as long as 30 years after 
documented infection (Ericsson et al., 1994). The development of 
more sensitive assays has facilitated even earlier detection of cytokines 
such as IFN-γ, which may be produced by both innate immune cells www.frontiersin.org  February 2011  | Volume 2  | Article 26  |  3
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Over the years, other small animal models for Francisella 
infection have been developed using rats, guinea pigs, hamsters, 
voles, and rabbits. Several recent reports, coupled with older 
literature, indicate that infection of Fisher 344 rats with differ-
ent Francisella strains may better approximate the phenotype of 
human infections that these other models. Both Fisher 344 and 
Lewis rats are much more resistant to F. novicida infection than 
mice, due at least in part to rapid production of nitric oxide 
from macrophages following recognition of the F. novicida LPS 
chemotype (Cowley et al., 1997; Ray et al., 2010). In a direct 
comparison, the intratracheal (IT) LD50 of Fisher 344 rats was 
recently reported to be 5 × 102 for Type A F. tularensis subsp. tula-
rensis (SchuS4); 1 × 105 for Type B F. tularensis subsp. holarctica 
(OR960246); 5 × 106 for F. novicida; and greater than 107 for LVS 
(Ray et al., 2010). Of note, however, Fisher 344 rats were highly 
susceptible to IP infection with a different Type B F. tularensis 
subsp. holarctica strain (FSC108), although still quite resistant 
to IP LVS infection (Raymond and Conlan, 2009). Nonetheless, 
overall the hierarchy of susceptibility of rats appears to gener-
ally reflect human Francisella infections, and provide a more 
satisfying profile than that of mice. Equally important, Fisher 
344 rats vaccinated IT, intradermally (ID), or subcutaneously 
(ID) with ∼107 LVS survived IT challenge with at least 100 LD50s 
of challenge with Type A F. tularensis subsp. tularensis (SchuS4; 
Wu et al., 2009; Ray et al., 2010). Thus this rat strain appears to 
provide both a useful model for both infection and immunologi-
cal studies for further analyses.
Despite the practical appeal of small animal models, studies 
using non-human primates remain important not only for basic 
studies of host–pathogen interactions but for testing of drugs, 
vaccines, and therapeutics. Historically, monkeys have been con-
sidered to be even more susceptible than humans to Francisella 
infection. Outbreaks of tularemia in various species of mon-
keys in both zoo and experimental colonies have been reported 
repeatedly (Splettstoesser et al., 2007). There is an extensive older 
literature using monkeys, particularly Rhesus monkeys, for both 
natural history and vaccination studies (Lyons and Wu, 2007; 
Kugeler et al., 2008). Most recently, interest in product develop-
ment has spurred renewed efforts to establish non-human pri-
mate models using species currently available for experimental 
studies. Marmosets (Callithrix jacchus) suffer lethal infection 
with as few as 10 CFU of Type A F. tularensis subsp. tularensis 
(SchuS4) administered by aerosol, with pathology that appears 
similar to that of humans. Infected marmosets further exhibited 
production of pro-inflammatory cytokines, as well as increased 
numbers of the major lymphoid and myeloid cell subpopulations 
in lungs and blood (Nelson et al., 2009, 2010). Similarly, the pro-
file of aerosol infection of African green monkeys (Chlorocebus 
aethiops) given ∼700  CFU  of  SchuS4  was  described  recently 
(Twenhafel et al., 2009), and studies in cynomolgus monkeys as 
well as comparisons between species are underway (Wilder and 
Gelhaus, 2009). While it is premature to draw conclusions about 
the relative strengths and weaknesses of each of these approaches, 
further studies will no doubt provide data that informs the value 
of different non-human primate models for both pathogenesis 
and immunological studies.
non-mammalIan InfectIon models
Two  groups  have  explored  insect  models  of  Francisella  infec-
tion. Both LVS (Vonkavaara et al., 2008) and F. novicida (Ahlund 
et al., 2010; Moule et al., 2010) productively infect and replicate 
in Drosophila melanogaster, both by infection of phagocytic fly 
hemocytes and by extracellular replication. Both efforts focused 
on the ability of the model to identify bacterial virulence factors; 
mutations in bacterial genes important to virulence in mouse 
models, notably pathogenicity island genes including mglA and 
others regulated by mglA, clearly contributed to virulence in flies. 
Given that deer flies are vectors of Francisella infection, however, 
it remains to be revealed whether the fly host biology discovered 
is applicable only to the vector, or also helpful in modeling human 
responses.
Initial  efforts  to  establish  Francisella  infection  of  zebrafish, 
another  genetically  tractable  system  that  has  a  more  complex 
immune system than Drosophila, have recently been reported as 
well. In the last 3–4 years, new Francisella spp. have been isolated 
from diseased fish, both wild and cultivated. The zebrafish study 
used one of these strains, and demonstrated productive experi-
mental infection followed by up-regulated expression of IL-1β, 
IFN-γ, and TNF-α, analogous to mammalian pro-inflammatory 
responses. There was no increase, and perhaps transient down-
regulation, of iNOS, however (Vojtech et al., 2009).
mammalIan InfectIon models
For all the obvious reasons, the majority of immunological studies 
of Francisella have used mouse models. The available data indicate 
that mice are a reasonable model of human immune responses, 
at least at a first approximation, but less satisfying as a model for 
pathogenicity. Inbred laboratory strains are readily susceptible 
to infection with all Francisella isolates tested to date; bacteria 
disseminate to the same target organs of the reticuloendothelial 
system, and infected tissues develop granulomatous pathologies 
that appear roughly comparable to lesions described in tissues of 
infected people. There is a major discrepancy between humans and 
mice in virulence and lethality, however. In mice, the LVS strain 
establishes a sublethal vaccinating infection when administered 
via skin inoculation, but kills mice at low doses when introduced 
by other routes, including intravenous (IV), intramuscular, or 
intraperitoneal (IP), and is intermediate for respiratory infections 
(Elkins et al., 2003). Importantly, infection with both Type A and 
Type B F. tularensis, as well as F. novicida, kills mice within a week 
with essentially any dose and when introduced by any route of 
infection. In contrast, as noted above, human Type B infections in 
particular are rarely lethal (Staples et al., 2006; Kugeler et al., 2008). 
Human F. novicida infections are quite rare, and when detected 
are sometimes associated with immunocompromised individuals 
(Hollis et al., 1989; Whipp et al., 2003; Leelaporn et al., 2008). To 
date, there is only one report of Francisella infection of HLA-DR4 
transgenic mice, with the goal of uncovering antigens recognized 
by human T cells (Yu et al., 2010); but as expected, these mice were 
equally susceptible to intranasal LVS infection as wild type mice. It 
remains to be determined whether “humanized” mice created by 
engraftment of human stem cells exhibit susceptibilities that better 
approximate human infection profiles.www.frontiersin.org  February 2011  | Volume 2  | Article 26  |  5
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in vivo Immune responses to Francisella novicida 
and mutants based on F. novicida
Although a comprehensive discussion of the relative virtues of 
conducting experimental studies using F. tularensis strains versus 
F. novicida strains is outside of the topic of this review, some general 
comments regarding immunological responses are pertinent here. 
For many years, only F. novicida was amenable to genetic manipula-
tion; efforts to transform F. tularensis strains with transposons or 
develop mutants via allelic exchange using traditional techniques 
either failed, or were of such low efficiency as to be impractical. 
Following recent concerted efforts to develop better genetic tools 
for manipulation of F. tularensis, this situation has changed greatly. 
A number of transposon banks and deletion mutants of F. tula-
rensis Type A, Type B, and LVS strains have been developed in the 
last ∼5 years. Nonetheless, manipulation of F. novicida remains 
considerably easier; further, this strain is exempt from Select Agent 
registration in the U.S., and generally used under BSL-2 laboratory 
conditions. Thus F. novicida remains popular for genetic studies, 
and mutants have frequently been used for in vivo infection studies, 
particularly those seeking virulence factors. However, when reading 
this literature, it is important to note that F. novicida’s name has 
been written as both F. novicida and later F. tularensis subsp. novic-
ida, and the appropriate current designation remains controversial 
(Busse et al., 2010; Huber et al., 2010; Johansson et al., 2010).
Francisella tularensis subsp. tularensis and holarctica clearly have 
strong genetic homologies with F. novicida, and findings regarding 
pathogenesis and cell biology made using F. novicida and its mutants 
have often been applicable to the biology of F. tularensis. However, 
there are important biological differences between F. novicida and 
F. tularensis strains that appear particularly problematic for immu-
nological studies. As discussed above, the virulence of F. novicida 
in both humans and various animal models is quite distinct from 
that of the F. tularensis subsp. In mice given F. novicida intranasally, 
the cell tropism in lungs is noticeably different from that for LVS 
and SchuS4. The latter two strains preferentially infect alveolar 
macrophages and later expand in macrophages, DCs, and neu-
trophils; in contrast, F. novicida starts in neutrophils and alveolar 
macrophages, and then expands in neutrophils while macrophages 
and DCs are lesser targets (Hall et al., 2008). Importantly, F. novicida 
expresses a structurally distinct chemotype of LPS that is more pro-
inflammatory in mice than the dominant LPS chemotype expressed 
by F. tularensis strains (Cowley et al., 1996; Kieffer et al., 2003; 
Gunn and Ernst, 2007). Although not yet examined directly, the LPS 
bioactivity may contribute to the observed sepsis-like syndrome 
that follows intranasal infection of mice with F. novicida (Mares 
et al., 2008). Each chemotype of LPS also appears to play distinct 
roles in virulence of the respective bacteria and in contributing to 
protection in mouse models (Thomas et al., 2007).
Studies of immune responses to F. novicida in mice consistently 
reveal a prominent role for B cells and antibodies that is consider-
ably more dramatic than LVS or fully virulent Francisella strains. 
The LD50 of F. novicida administered to inbred mice ID is about 103. 
The ID LD50 of F. novicida administered to B cell knockout mice is 
less than 5 × 101, and those that do survive vaccination are severely 
compromised compared to wild type mice for survival of second-
ary lethal IP challenge with LVS (Chou and Elkins, manuscript 
in preparation). Similarly, mice vaccinated IN with attenuated 
mutants in iglB or iglC of F. novicida have large amounts of both 
IgG1 and IgG2a serum anti-Francisella antibodies, which adoptively 
transfer protection against F. novicida challenge to recipients in the 
absence of primed T cells (Pammit et al., 2006; Powell et al., 2008). 
For the iglC mutant of F. novicida, vaccinated mice depleted of CD4+ 
T cells at the time of challenge with F. novicida survived, and thus 
protection depended on the presence of antibodies but not effector 
T cells (Powell et al., 2008). Collectively, the mechanistic data to 
date paints a picture that is quite distinct from studies using LVS 
as a vaccine or challenge with virulent Francisella.
systemIc versus mucosal ImmunIty to F. tularensis
Although Francisella infection can be initiated via multiple routes, 
historically the majority of studies in the Francisella murine model 
have focused on ID or SC exposure to the pathogen. In partic-
ular, ID infection with LVS has been utilized because this route 
approximates the most likely method of vaccination in humans 
(scarification or SC inoculation), and also conveniently allows 
for mechanistic studies of immunity after a sublethal infection 
in mice. More recent studies have focused on respiratory infec-
tions, given the interest in biodefense applications. Mice are much 
more susceptible to Francisella infections initiated via pulmonary 
routes as compared to the ID/SC route. For LVS, the IN LD50 is 
∼102–104 bacteria, whereas infection via the ID/SC route exhibits 
an LD50 of ∼106–107 bacteria. For the more virulent Type A and 
Type B F. tularensis strains, both routes of primary infection are 
rapidly lethal, although protection against secondary respiratory 
challenge is much more difficult to achieve than protection against 
ID/SC challenge (Chen et al., 2003). Indeed, to date reasonable 
protection against virulent Type A respiratory challenge has only 
been achieved following mucosal (but not parenteral) LVS vac-
cination (Conlan et al., 2005; Wu et al., 2005; KuoLee et al., 2007). 
These observations recall theories of the “compartmentalization” 
of the mucosal immune system (Gill et al., 2010). In support of this 
concept, respiratory vaccination is not the only mucosal immuni-
zation route that is protective against respiratory challenge: LVS 
immunization via the oral route also results in survival of Type 
A pulmonary challenge, whereas ID/SC immunization does not 
(KuoLee et al., 2007). The immune mechanisms that are uniquely 
induced by mucosal – but not parenteral – vaccination remain to 
be identified. Recent data indicates that important cytokines such as 
IL-17A are preferentially produced in LVS-infected lungs following 
respiratory – but not parenteral – infection (Woolard et al., 2008; 
Cowley et al., 2010). Thus certain immune mediators may be of 
greater importance depending on the initial tissue encountered 
during vaccination and/or challenge; this possibility remains an 
interesting avenue of future investigation.
As noted above and in detail in another article in this issue, one 
theme that has emerged in recent years is the ability of Francisella to 
initially suppress or avoid induction of early immune responses fol-
lowing primary respiratory infection. Although multiple cell func-
tions are clearly suppressed by both LVS and Type A F. tularensis, 
virulent Type A strains execute a broader range of immunosup-
pression that likely contributes to their increased virulence (Bosio 
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another article in this issue, here we focus our discussion on the 
current knowledge of the contribution of TLRs to the initiation of 
in vivo host responses to Francisella.
Current  in  vitro  and  in  vivo  evidence  indicates  that  TLR2 
and MyD88 are critical mediators of inflammatory responses to 
Francisella. In vitro studies have demonstrated that TLR2 is required 
for murine DCs to activate NF-KB, produce TNF-α, and up-regulate 
maturation markers in response to LVS (Katz et al., 2006). Similarly, 
TLR2 was required for induction of a range of pro-inflammatory 
cytokine genes (e.g., TNF-α, IL-1β, KC, p40, RANTES, IFN-γ, IL-6, 
IFN-β, MCP-1, and iNOS) by peritoneal macrophages in response 
to LVS (Cole et al., 2007; Abplanalp et al., 2009). Full signaling 
via TLR2 in LVS-infected macrophages required the adaptor mol-
ecules MyD88 and TIRAP (Cole et al., 2010). Consistent with the 
membrane-bound nature of TLR2, LVS co-localized intracellularly 
within a TLR2/MyD88-containing phagosome (Cole et al., 2007). 
Interestingly, an LVS mutant that cannot escape the phagosome 
induced  greatly  increased  expression  of  TLR2-dependent  pro-
inflammatory genes (such as TNF-α), and decreased expression 
of genes that rely on cytosolic recognition of bacteria (such as 
IFN-β; Cole et al., 2008). These data underscore the existence of 
the two separate arms of pathogen detection and early cytokine 
responses – those cytokines whose production is initiated solely 
via TLR signaling (TNF-α, IL-6), and those cytokines that require 
both TLR and NLR signaling (IFN-β, IL-1β).
In vitro data are supported by numerous in vivo studies that 
demonstrate increased susceptibility of TLR2 and MyD88 KO mice 
to LVS infection (Collazo et al., 2006; Malik et al., 2006; Abplanalp 
et al., 2009). Intranasal LVS infection of TLR2 KO mice resulted 
in increased mortality and decreased survival times as compared 
to their WT counterparts, accompanied by higher bacterial organ 
burdens and lower levels of TNF-α and IL-6 in the lungs (Malik 
et al., 2006; Abplanalp et al., 2009). Although TLR2 KO mice were 
significantly more susceptible to LVS infection than wild type mice 
via both the IN and ID routes, mice were consistently able to sur-
vive lower doses of LVS. This was in stark contrast to MyD88 KO 
mice, which were exquisitely susceptible to even the smallest doses 
of LVS delivered via both routes. This indicates a role for MyD88 
in LVS infection that extends beyond its function as an adaptor 
for TLR2 signaling (Collazo et al., 2006; Abplanalp et al., 2009). 
Other MyD88-dependent molecules that have been tested in the 
LVS infection model include IL-18, IL-1R, TLR4, TLR1, TLR6, and 
TLR9 (for summary, see Table 2). Although most have not been 
exhaustively studied, mice singly deficient for these molecules did 
not exhibit notably increased susceptibility to LVS infection as com-
pared to their WT counterparts (Collazo et al., 2006; Abplanalp 
et al., 2009). Similarly, TLR2/9 double KO mice readily survived 
doses of up to 10
5 LVS given ID (Chou and Elkins, manuscript in 
preparation). Further studies in mice deficient in multiple MyD88-
dependent receptors would be needed to rule out the possibility of 
redundancy and/or compensatory effects.
Investigations of the bacterial ligands responsible for TLR rec-
ognition of Francisella indicate that LVS expresses lipoproteins that 
can activate HeLa cells transfected with either TLR2/TLR1 or TLR2/
TLR6 heterodimers. Specifically, the lipoproteins Tul4 and FTT1103 
stimulated activity via the TLR2/1 heterodimer, and induce expres-
sion of a panel of chemokines in both human peripheral blood 
as  prostaglandin-E2  (PGE2)  production  or  reduced  levels  of 
CD14 – may be operative primarily in certain tissues such as the 
lung (Woolard et al., 2008). Thus, both the route of inoculation and 
the strain of Francisella can have a widely different impact on the 
quantity and quality of immune responses measured. Differences 
in these factors can often make it difficult to draw comparisons 
between different studies.
medIators of Innate Immune responses
complement
Recent studies documenting that F. tularensis and F. novicida can 
survive extracellularly in whole blood in vitro and in vivo dur-
ing mouse infections (Forestal et al., 2007; Yu et al., 2008) have 
generated new perspectives on the role of extracellular mediators 
of immunity during infection. F. tularensis is clearly resistant to 
the bactericidal effects of sera from a variety of species, a feature 
that was initially associated with cell surface carbohydrate struc-
tures described as a capsule (Hood, 1977). More recently, however, 
studies using Francisella strains with targeted mutations in LPS 
biosynthesis genes have demonstrated that complement resist-
ance is critically dependant upon LPS O antigen (Thomas et al., 
2007; Clay et al., 2008). Although resistant to its bactericidal effects, 
Francisella clearly binds by complement components: complement-
derived opsonins and complement receptors enhance phagocytic 
uptake of F. tularensis by a variety of cell types, including human 
and mouse monocytes and macrophages (Clemens et al., 2005; 
Pierini, 2006; Schulert and Allen, 2006), and human monocyte-
derived DCs (Ben Nasr et al., 2006; Ben Nasr and Klimpel, 2008). 
Indeed, C3 complement components – but not the lethal C5b-C9 
membrane attack complex – were shown to be deposited on the 
cell surface of F. tularensis after incubation in human sera. These 
C3-derived opsonins enhanced phagocytic uptake by human DCs 
via a process that promoted intracellular survival, bacterial growth, 
and DC death (Ben Nasr et al., 2006; Ben Nasr and Klimpel, 2008). 
This strategy of resistance to complement killing, and the use of 
complement opsonins to gain entry into an intracellular niche that 
supports bacterial growth, is likely an important virulence deter-
minant of Francisella. In support of this hypothesis, Francisella O 
antigen mutants are attenuated in the mouse model of infection 
(Thomas et al., 2007).
pattern-recognItIon receptors and early cytokIne 
productIon
Host  cells  express  a  variety  of  germline-encoded  “pattern-
  recognition  receptors”  (PRRs),  which  recognize  a  number  of 
evolutionarily conserved molecular patterns expressed only by 
pathogens. PRRs include the membrane-anchored Toll-like recep-
tors (TLRs) and the cytosolic NOD-like receptors (NLRs). Because 
Francisella initially resides in a membrane-bound phagosome prior 
to escape into the cytosol, the bacterium has the potential to interact 
with both membrane and cytosolic PRRs. Indeed, recent evidence 
has shown that bacterial DNA engaged the cytoplasmic NLR sen-
sor “absent in melanoma 2” (AIM2) within Francisella-infected 
macrophages, a process that was necessary to initiate inflamma-
some assembly, caspase-1 activation, and IL-1β release (Jones et al., 
2010; Rathinam et al., 2010; Ulland et al., 2010). Since the role of 
the inflammasome in Francisella infection is reviewed in detail in www.frontiersin.org  February 2011  | Volume 2  | Article 26  |  7
Cowley and Elkins  Immunity to Francisella
  demonstrated that it is uniquely tetra-acylated and monophospho-
rylated, both structural properties that can reduce the endotoxicity 
of LPS (Gunn and Ernst, 2007). Indeed, the only biological activ-
ity ascribed to F. tularensis LPS (Ft-LPS) thus far is its ability to 
bind and stimulate rapid antibody production by the “innate” B 
lymphocyte subset B1a cells, and this function was clearly TLR4-
independent (Cole et al., 2009); see below. Although Francisella 
LPS clearly has little if any TLR4-dependent stimulatory activities 
(Duenas et al., 2006), one recent study revealed that the F. tularensis 
heat shock protein DnaK can initiate cytokine production by DCs 
through TLR4 in vitro (Ashtekar et al., 2008). Despite the potential 
for Francisella to stimulate TLR4 through non-LPS ligands, TLR4-
deficient mice do not exhibit increased susceptibility to Francisella 
infection, indicating that this TLR is not critical for in vivo defense 
(Chen et al., 2004, 2005b; Collazo et al., 2006).
More recently, the downstream effects of TLR2/MyD88 signaling 
have been studied in more detail. LVS infection of bone marrow-
derived macrophages (BMDMs) induced TLR2-dependent splicing 
of mRNA for XBP-1, a transcription factor necessary for production 
of TNF-α and IL-6 mRNA. The importance of XBP-1 in resistance 
to LVS infection was confirmed by the presence of higher levels of 
mononuclear cell (PBMC) and mouse bone marrow-derived DCs 
(Thakran et al., 2008). A role for TLR6 in recognition of LVS was 
similarly demonstrated by the inability of bone marrow-derived 
DCs harvested from TLR6 KO mice to produce TNF-α in response 
to LVS (Katz et al., 2006). Conversely, in other studies, macrophages 
from TLR6 KO mice infected with LVS expressed higher levels of 
TNF-α, IL-6, and MCP-1 than their WT counterparts, and, as men-
tioned above, TLR6 KO mice exhibit no increased susceptibility to 
LVS infection (Abplanalp et al., 2009). Thus, it is possible that in 
some circumstances TLR6 and TLR1 are redundant in their abilities 
to recognize LVS ligands in concert with TLR2.
Bacterial  LPS  is  usually  one  of  the  first  Gram  negative 
  pathogen-associated  molecular  patterns  to  be  detected  by  the 
immune system, specifically targeted by the PRR TLR4. However, 
studies of Francisella LPS over the years have found it to be bio-
logically inactive, unable to induce production of pro-inflamma-
tory cytokines from all cell types tested. Subsequent studies have 
shown that Francisella LPS is not recognized by either human or 
murine TLR4 or TLR2, and further cannot act as an antagonist 
to block binding of Salmonella LPS to TLR4 (Duenas et al., 2006; 
Hajjar et al., 2006). Elucidation of the structure of Francisella LPS 
Table 2 | The contribution of cytokine receptors, toll-like receptors, and other effector components of immune responses to in vivo murine infection 
with Francisella tularensis*.
Component  Effect of depletion/knockout§  Cellular source(s)‡
 1 ° infection  2° infection  Innate  Acquired (T cells)
CyToKINE RECEpToRS
IL-4R  Slightly more susceptible  N/A  M∅s  N/A 
  at high dose (3 × 103 IN)
IL-4Rα  Less susceptible  N/A  N/A  N/A 
  to lethal dose (104 IP)
IFNαR1  Less susceptible† (ID)  N/A  N/A  N/A
IL-1R  No change (ID)  Survive lethal 106 IP challenge  N/A  N/A
TNFR1/2  Lethal at low doses  N/A  M∅s  CD4+, CD8+ 
  (102 aerosol and 20 ID)
ToLL-LIKE RECEpToR-RELATEd
TLR2  More susceptible at high/moderate  Survive lethal 106 IP challenge  M∅s, DCs  N/A 
  doses (4 × 103 IN and 4 × 104 ID)
MyD88  Lethal at all doses (IN and ID)  N/A  M∅s, DCs  N/A
TLR4  No change (IN and ID)  Survive lethal 106 IP challenge  M∅s, DCs  N/A
TLR9  No change (ID)  Survive lethal 106 IP challenge  N/A  N/A
TLR6  No change (IN)  N/A  M∅s, DCs  N/A
TLR1  No change (IN)  N/A  N/A  N/A
oTHER
STAT1  Lethal at high dose† (103 aerosol)  N/A  M∅s  N/A
iNOS  Lethal at all doses (ID and aerosol)  N/A  M∅s  N/A
p47phox  Sublethal at low doses; lethal  N/A  M∅s  N/A 
  at moderate doses (LD50 4 × 103 ID)
MMP-9  Less susceptible (IN)  N/A  N/A  N/A
*Data presented are for LVS unless otherwise noted.
†Data for F . novicida infection.
§Data presented describe changes in organ CFUs or survival differences as compared to WT mice. All bacterial doses are expressed in terms of CFU.
‡Only the cell types for which there is direct or indirect evidence of expression during Francisella infection (in vitro or in vivo) are listed.
N/A, data not available; ID, intradermal; IN, intranasal; IP , intraperitoneal; M∅s, macrophages; DCs, dendritic cells.
For references, see corresponding text.Frontiers in Microbiology  |  Cellular and Infection Microbiology    February 2011  | Volume 2  | Article 26  |  8
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LVS in the organs of XBP-1-deficient mice as compared to WT mice 
after aerosol infection (Martinon et al., 2010). In a different study, 
F. novicida infection of human PBMCs and murine macrophages 
resulted in up-regulation of the micro-RNA miR-155 in a manner 
that was dependent on TLR2 and MyD88. This micro-RNA blocks 
translation of SHIP, a negative regulator of the PI3K/Akt pathway 
(Cremer et al., 2009). The net effect of the release of Akt from 
inhibition was an increase in pro-inflammatory gene expression. 
Indeed, mice that express a constitutively active form of Akt survive 
an otherwise lethal F. novicida infection (Rajaram et al., 2009). 
Interestingly, experiments using the virulent Type A F. tularensis 
SchuS4 indicated that SchuS4 had the opposite effect on miR-155 
induction, namely down-regulating the pro-inflammatory cytokine 
response. These results thus reveal one mechanism by which viru-
lent Francisella may inhibit early immune responses (Cremer et al., 
2009). These data are also in agreement with Affymetrix microarray 
and Western blot analyses of human PBMCs that indicated down-
regulation of the PI3K/Akt pathway and TLR2 after SchuS4, but not 
F. novicida, infection (Butchar et al., 2008a; Melillo et al., 2010).
cytokInes and cHemokInes In prImary InfectIon wItH 
Francisella
Cytokine production during Francisella infection is a very active 
area of research, and our understanding of the important cytokine 
and chemokine mediators continues to evolve (for an overview, 
refer to Figure 1). Similar to other intracellular pathogens, rapid 
production of pro-inflammatory and Th1-type cytokines is critical 
for initial control of Francisella infection in all settings examined to 
date. However, as noted earlier, there is a striking lack of crucial pro-
inflammatory cytokines during the first 48 h of murine pulmonary 
Francisella infection. It is not until after the first 48–72 h of murine 
infection that key cytokines and chemokines become readily detecta-
ble. During virulent F. tularensis respiratory infection of mice, mRNA 
levels of essential antimicrobial cytokines such as IFN-γ and TNF-α 
rose in the lungs between days 2 and 4 (Andersson et al., 2006b), and 
serum/distal organ levels of pro-inflammatory mediators such as 
RANTES, IL-6, and IL-1β became detectable on days 3–4 (Conlan 
et al., 2008). However, after 2 days of unrestricted bacterial growth, 
key organs such as the lungs and liver harbor extremely high bacte-
rial burdens. Thus the relatively late up-regulation of antimicrobial 
host immune mechanisms appears to be too late to prevent death. 
Indeed, a number of studies support the hypothesis that augment-
ing production of pro-inflammatory cytokines very early during 
infection can be beneficial. For example, mice administered either a 
synthetic TLR4 agonist, the TLR3 agonist poly I:C, or recombinant 
IL-12 shortly before inhalation of Francisella exhibited diminished 
organ bacterial burdens, and enhanced survival (Duckett et al., 2005; 
Lembo et al., 2008; Pyles et al., 2010).
The  widespread  up-regulation  of  multiple  cytokines  and 
chemokines by day 3 after murine F. novicida pulmonary infec-
tion resembles a “cytokine storm” that is associated with severe 
sepsis – a condition characterized by excessive production of pro-
inflammatory cytokines that culminates in capillary leakage, tissue 
injury, and organ failure. One mediator of severe sepsis, the nuclear 
DNA-binding protein HMGB-1, was strongly up-regulated and 
localized extracellularly in mouse lungs by day 3 after F. novicida 
intranasal infection (Mares et al., 2008). Thus damage-associated 
molecular  pattern  molecules  such  as  HMGB-1  are  shed  from 
dying host cells, and may be responsible for lethal severe sepsis. 
This striking outcome was age-dependent: older mice given a pul-
monary F. novicida infection had significantly increased survival 
and an associated reduction in development of hypercytokinemia 
and cell death (Mares et al., 2008). Whether a similar intriguing 
phenomenon is responsible for mortality during LVS or virulent 
F. tularensis infection in vivo remains to be determined, but macro-
phages infected in vitro with SchuS4 also release HMGB-1 (Mares 
et al., 2008).
Consistent with the ability of virulent F. tularensis strains to 
initially suppress – and then ultimately overwhelm – the murine 
immune response, most studies examining the role of various 
cytokines and chemokines in this infection model have shown 
that  mice  deficient  for  such  key  cytokines  as  IFN-γ,  TNF-α, 
lymphotoxin-α, and iNOS exhibit the same extreme susceptibil-
ity to infection via the pulmonary and parenteral routes as fully 
immunocompetent mice (Chen et al., 2004; Zhang et al., 2008). In 
contrast, the lower virulence of LVS allows for the determination of 
a spectrum of susceptibility for the different cytokines and chem-
okines that contribute to immunity. Thus far, the only cytokine-
deficient mice that are exquisitely susceptible to all doses of LVS 
delivered via any route are those that lack either of the canonical 
Th1 cytokines, IFN-γ or TNF-α (for summary, see Table 3; Elkins 
et al., 2007). Mice deficient for either cytokine usually die within 
a week after inoculation, suggesting that early innate immune cell 
production of IFN-γ and TNF-α is critical for survival. A recent 
study of the cell types that produce IFN-γ after primary sublethal 
LVS ID infection revealed that a wide variety of liver and spleen 
innate immune cells produce IFN-γ during the first 7 days after 
infection, including NK cells, neutrophils, DCs, and cells that match 
the staining profile of “NK DCs” (De Pascalis et al., 2008). Given 
that both IFN-γ and TNF-α are important for macrophage produc-
tion of RNI, and that RNI are effective mediators of inhibition of 
LVS intramacrophage growth in vitro, it is likely that induction of 
iNOS-derived products is one critical early role for these cytokines 
in vivo (Anthony et al., 1992; Lindgren et al., 2004, 2005). Indeed, 
iNOS-deficient mice die following sublethal LVS infections initiated 
via a variety of routes (Lindgren et al., 2004), although are not as 
dramatically impaired as IFN-γ or TNF-α knockout mice. Although 
the cells that produce TNF-α in response to ID LVS infection have 
not yet been systematically identified, the role of TNF-α during 
in vivo primary ID LVS infection clearly includes induction of reac-
tive nitrogen species (RNS; Cowley et al., 2008). Further, membrane 
TNF-α is sufficient to partially mediate resistance to primary LVS 
ID infection, since mice that express only the membrane-bound 
form of TNF-α (and not the soluble form) exhibited an intermedi-
ate level of susceptibility to LVS infection, as well as intermediate 
levels of RNS (Cowley et al., 2008).
In contrast to the prototypic Th1 cytokines, Th2 mediators have 
not been examined in much detail during in vivo infection. Mice 
treated with anti-IL-4 antibodies and then infected with LVS ID 
exhibited an ID LD50 that was comparable to wild type mice, if 
not higher (Leiby et al., 1992), while IL-4 knockout mice were 
found to be only slightly more susceptible to IN LVS pulmonary 
infection (Ketavarapu et al., 2008), and IL-10 knockout mice were 
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occurs in mice given LVS infection via other routes awaits compre-
hensive characterization: mice deficient for p35, p40, p19, and/or 
their associated receptors were more susceptible to pulmonary LVS 
infection, but the studies to date only used doses approaching the 
LD50 (Duckett et al., 2005; Lin et al., 2009).
IL-17A has an unexpected and critical role in primary LVS pul-
monary murine infection. First detectable in mouse lungs by day 3 
after infection, by days 6–7 the IL-17A-producing T cells identified 
in mouse lungs included CD4+ T cells, CD8+ T cells, double nega-
tive (DN) T cells, and γ/δ T cells (Lin et al., 2009; Cowley et al., 
2010; Markel et al., 2010). The role of IL-17A in LVS pulmonary 
infection appears to be multi-fold; IL-17A stimulates LVS-infected 
DCs to up-regulate production of IL-12 and IFN-γ in vitro, and 
stimulates IFN-γ production by ovalbumin-specific transgenic T 
cells. Thus IL-17A appears poised to augment early IFN-γ produc-
tion and aid in polarization of Th1 cells (Lin et al., 2009). However, 
IL-17A also has a role in the later stages of in vivo infection (days 
10–21), when T cell-mediated immunity is critical for clearance 
of the infection: IL-17A knockout mice given a sublethal LVS pul-
monary infection exhibit significantly increased bacterial organ 
burdens at these late time points (Cowley et al., 2010). Higher 
numbers of IFN-γ-producing CD4+ and DN T cells were present in 
the lungs of IL-17A KO mice than their WT counterparts at these 
later time points, indicating that although IL-17A has a role in 
inducing early Th1 immunity, IFN-γ-producing T cells are capable 
of responding to the infection at later time points. Importantly, the 
discovery that IL-17A can act in concert with IFN-γ to inhibit LVS 
intracellular growth in   macrophages and alveolar type II epithelial 
(Metzger et al., 2007). Interestingly, as discussed in more detail 
below, IL-4 receptor α chain knockout mice were less susceptible 
to lethal IP LVS challenges (Shirey et al., 2008).
Unlike IFN-γ and TNF-α, the role for IL-12 in primary in vivo 
LVS infection is more nuanced. IL-12 is a heterodimer that consists 
of two distinct proteins, the p35 and p40 subunits. In addition to 
constituting one component of IL-12, the p40 subunit can also pair 
with another protein, denoted p19, to produce the IL-23 heterodimer. 
Thus, mice deficient for p35 lack IL-12, whereas mice deficient for 
p40 lack both IL-12 and IL-23. Although both p35- and p40-deficient 
mice can survive sublethal LVS ID infection, they are both clearly 
compromised. Whereas 35-deficient mice exhibit higher bacterial 
organ burdens and cleared the infection more slowly than WT 
mice, p40 KO mice were unable to clear ID LVS infection, exhibiting 
chronic high liver and spleen bacterial numbers (Elkins et al., 2002). 
Both types of LVS-infected knockout mice exhibit reduced levels of 
serum IFN-γ (Elkins et al., 2002), a finding that is consistent with 
the role of IL-12 in positive feedback regulation of IFN-γ production 
by T cells and NK cells. Interestingly, p40-deficient mice exhibited 
a greater defect in IFN-γ-production than their p35 counterparts, 
indicating that IL-23 may have an additional role in inducing IFN-γ 
production (Elkins et al., 2002). Indeed, recent studies found that 
IL-23 produced by Francisella-infected human monocytes induced 
NK cell production of IFN-γ, indicating that both IL-23 and IL-12 
can positively regulate IFN-γ production (Butchar et al., 2007, 2008b). 
The unique phenotype of p40 knockout mice indicates that p40 – and 
by extension, IL-23 – has an as-yet unidentified role in the clearance 
of sublethal murine LVS ID infection. Whether a similar phenotype 
Table 3 | The contribution of cytokines and chemokines to in vivo murine infection with Francisella tularensis*.
Component  Effect of depletion/knockout§  Cellular source(s)‡
 1 ° infection  2° infection  Innate  Acquired (T cells)
IFN-γ  Lethal at all  Sublethal at some challenge  M∅s, DCs, NK  CD4+, CD8+, and DN 
  doses (ID, IV, and IN)  doses (2 × 106 IV and ∼102 IP)  cells, “NK DCs”
TNF-α  Lethal at all doses (ID, IV, and IN);   Sublethal at lower challenge doses (9 × 103 IV);   M∅s, DCs  CD4+, CD8+ 
  memTNF survive only low doses (∼102 ID)  memTNF survive high lethal 5 × 105 IP challenge
IL-17A  Sublethal at moderate doses (104 ID and  N/A  γδ T cells  CD4+, CD8+, and DN 
  102 IN); lethal at high doses (∼103 IN and IT) 
IL-18  No change (ID)  Survive high lethal 106 IP challenge  N/A  N/A
IL-4  No change (ID)  N/A  Mast cells  N/A
IL-10  More susceptible at high dose (103 IN)  N/A  N/A  N/A
IL-12p35  Sublethal at moderate doses, infection cleared  Survive high lethal 5 × 106 IP challenge  M∅s, DCs  N/A 
 ( ∼106 ID); lethal at high doses (∼103 IN and IT)
IL-12p40  Sublethal at moderate doses, chronic infection  Survive high lethal 106 IP challenge  M∅s, DCs  N/A 
 ( ∼106 ID); lethal at high doses (∼103 IN and IT)
IL-23p19  Lethal at high doses (∼103 IT)  N/A  N/A  N/A
IL-22  No change (IT)  N/A  N/A  N/A
Mig/CXCR3  No change (ID)  Survive high lethal IP challenge  N/A  N/A
CX3CR1  No change (IN)  N/A  N/A  N/A
*Data presented are for LVS unless otherwise noted.
§Data presented are for survival (or organ CFUs) as compared to WT mice.
‡Only the cell types for which there is direct or indirect evidence of expression during Francisella infection (in vitro or in vivo) are listed.
N/A, data not available; IN, intranasal; IT, intratracheal; ID, intradermal; IV, intravenous; IP , intraperitoneal; MTD, mean time to death; M∅s, macrophages; DCs, 
dendritic cells.
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(Anthony et al., 1991; Ben Nasr et al., 2006; Katz et al., 2006; Chase 
et al., 2009; Chase and Bosio, 2010). Further, Francisella can grow 
in vitro in murine phagocytes harvested from a variety of differ-
ent tissues, including elicited peritoneal macrophages, alveolar 
macrophages, BMDMs, bone marrow-derived DCs, and alveolar 
DCs (Anthony et al., 1991; Polsinelli et al., 1994; Bosio and Elkins, 
2001; Bosio et al., 2007). In the absence of exogenous factors that 
induce activation, intracellular bacterial growth continues unre-
stricted until death of the host cell; at high multiplicities of LVS 
infection, this process results in caspase 3-dependent apoptosis 
of macrophages in vitro (Lai et al., 2001; Lai and Sjostedt, 2003). 
Although this phenomenon has not been demonstrated in vivo 
with LVS, virulent Type A Francisella induced widespread cas-
pase 3-dependent apoptosis of macrophages in the organs of mice 
infected IN. Thus unrestricted growth of Francisella can induce 
apoptotic death of infected host cells in vivo as well as in vitro 
(Wickstrum et al., 2009).
cells (ATII) in vitro indicates that IL-17A can be a potent effector 
cytokine with more than just regulatory properties (Lin et al., 2009; 
Cowley et al., 2010).
IL-17A is perhaps best known for its ability to recruit neutrophils 
to the site of infection. In LVS pulmonary infection, IL-17A-deficient 
mice exhibited decreased levels of lung G-CSF that was accompanied 
by a reduction in the proportion of lung neutrophils at early time 
points (days 4 and 6) after infection (Lin et al., 2009; Cowley et al., 
2010). Interestingly, type 1 Interferon receptor knockout mice exhibit 
increased resistance to ID F. novicida infection, a phenomenon that 
was associated with the ability of Type I IFNs to down-regulate the 
number of IL-17A+ γ/δ T cells and diminished recruitment of neu-
trophils to infected spleens (Henry et al., 2010). A similar Type I IFN-
mediated negative regulation of γ/δ T cell IL-17A production was also 
observed in mice infected IN with SchuS4, as well as mice given IV L. 
monocytogenes infection. Thus, low levels of IL-17A production by γ/δ 
T cells during Francisella infection may be a consequence of negative 
regulation effected by Type I IFNs. This outcome was at least partially 
attributed to the ability of type I IFNs to induce IL-27 production by 
Francisella-infected macrophages (Henry et al., 2010).
The role of chemokines in host responses to Francisella infec-
tion is only beginning to be elucidated. Potent mediators of cell 
trafficking, chemokines are responsible for drawing critical cell 
types to the site of infection. Indeed, multiple cell types have been 
shown to produce chemokines in response to Francisella infection, 
including DCs, endothelial cells, alveolar type II cells, and macro-
phages. Despite the abundant production of many chemokines 
in response to Francisella infection, only a few have been directly 
examined to date. CCR2 knockout mice, which lack responses to 
MCP-1/3/5 group of macrophage chemotactic proteins, are quite 
susceptible to ID LVS infection compared to knockout mice, and 
fail to exhibit increases in numbers of responding lymphoid and 
myeloid cells typically found in the spleens of LVS-infected wild 
type mice (Meierovics and Elkins, manuscript in preparation). 
However, mice lacking Mig or its receptor CXCR3 did not exhibit 
increased susceptibility to primary sublethal ID or secondary lethal 
IP LVS challenges (Park et al., 2002). Similarly, mice deficient for 
the chemokine receptor CX3CR1 were not more susceptible to IN 
LVS infection, although they did exhibit modest but significant 
dysregulation in recruitment of monocytes, neutrophils, and DCs 
to the lungs (Hall et al., 2009). Chemokines and/or their receptors 
are functionally redundant, so future studies utilizing mice that 
are multiply deficient for these factors will no doubt be needed 
to better define the critical roles of chemokines during in vivo 
Francisella infection.
Innate Immune responses followIng InteractIons 
of Francisella wItH Host cells
macropHages and dendrItIc cells
The virulence of Francisella has long been associated with its abil-
ity to exploit host phagocytic cells to support its own growth. In 
particular, the ability of macrophages and DCs from a variety of 
different host tissues to act as a replicative niche, as well as pro-
vide antimicrobial effector functions, has been intensively studied. 
Resident peritoneal macrophages from rats, mice, and guinea pigs, 
as well as human peripheral blood monocytes and monocyte-
derived DCs, support Francisella growth when infected in vitro 
FIguRE 1 | Components of murine innate and adaptive immune 
responses to Francisella. (1) The initial interaction of Francisella with host 
cells, such as macrophages, dendritic cells, epithelial cells, and endothelial 
cells, stimulates production of pro-inflammatory cytokines and chemokines 
(2a) in a manner that is dependent upon MyD88, TLR2, and other unidentified 
receptors that signal through MyD88. Bacterial DNA engagement of the 
NOD-like receptor (NLR) AIM2 may also be critical for inflammasome 
assembly and release of IL -1β. Simultaneously, important innate immune cells 
recruited to the area of infection produce effector cytokines such as IL -12p40, 
TNF-α, IFN-γ, and IL -17A (2b) that influence T cell development (3), and induce 
host cell production of antimicrobial molecules (4). In addition to the classic 
TH1-type cytokines, other mediators include mast cell production of IL -4, 
which can directly inhibit Francisella intramacrophage growth, and B-1a B cell 
production of anti-LPS antibodies that limit intraperitoneal infection. PMNs are 
essential for survival of Francisella infections initiated via some routes, but fail 
to eradicate intracellular organisms in vitro, so their contribution to infection 
remains unclear. After several days, activation and expansion of Francisella-
specific T cells and B cells occurs (3). αβ T cells are essential for clearance of 
primary infection, and produce effector cytokines such as IL -17A and IFN-γ, as 
well as the membrane-bound and soluble forms of TNF-α. These factors 
presumably amplify and extend activation of infected host cells to limit 
Francisella intracellular growth through production of reactive oxygen and 
nitrogen intermediates, as well as other unidentified antimicrobials (4). 
Asterisks (*) indicate host cells that have been shown to harbor intracellular 
Francisella. The blue box indicates cell types that are neither fully innate nor 
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pro-inflammatory cytokine production and reduced expression of 
alternative activation markers (Shirey et al., 2008). Similarly, lethal 
pulmonary F. novicida infection resulted in the development of 
alternatively activated macrophages in mouse lungs (Mares et al., 
2010). Alternative macrophage activation in the F. novicida model 
was exacerbated by the accumulation of dead cell debris in vitro and 
the poor ability of F. novicida-infected macrophages to perform effe-
rocytosis (the uptake and clearing of dead cells; Mares et al., 2010). 
Thus, it appears that during lethal Francisella infections, alternative 
activation of macrophages diminishes pro-inflammatory cytokine 
production and the generation of macrophage effector mechanisms, 
and may contribute to the progression of lethal disease.
Using several different F. tularensis strains in the mouse model 
of pulmonary infection, studies have demonstrated that both DCs 
and macrophages in the lung were infected within 1 h after inocula-
tion; these remained the predominant infected cell types by 24 h 
after infection (Bosio and Dow, 2005; Hall et al., 2008). Indeed, 
Francisella  grows  unrestricted  within  both  human  and  mouse 
DCs in vitro until the host cells die (Ben Nasr et al., 2006; Bosio 
et al., 2007). In vitro and in vivo evidence indicates that Francisella-
infected human and mouse DCs are actively immunosuppressed 
by the bacterium. Both are impaired in the ability to produce pro-
inflammatory cytokines, and are refractory to stimulation with 
potent immunomodulators such as E. coli LPS (Bosio et al., 2007; 
Chase et al., 2009). This immunosuppression has been attributed to 
a variety of factors, including the ability of SchuS4 to increase pro-
duction of the immunosuppressive cytokine TGF-β (an indicator 
of alternative macrophage activation, as described above), as well 
as the absence of CD14 expression by pulmonary DCs (Bosio et al., 
2007; Chase and Bosio, 2010). IN administration of soluble CD14 
to SchuS4-infected mice increased lung cytokine production, and 
reduced SchuS4 replication in the lungs and dissemination to the 
spleen (Chase and Bosio, 2010). Thus CD14 increased the capacity 
of DCs to “detect” SchuS4 infection, although paradoxically CD14 
is not normally abundant in pulmonary tissues and thus its paucity 
may contribute to SchuS4 immune evasion. Interestingly, recent 
data has shown that DCs not only serve as a silent replicative niche 
for Francisella after respiratory infection, but they also transport 
the pathogen to the mediastinal lymph nodes, and therefore may 
play a prominent role in early pathogen dissemination (Bar-Haim 
et al., 2008).
non-pHagocytIc cells
In recent years the spectrum of cell types infected by Francisella 
has broadened to include non-phagocytic cells, such as kidney 
epithelial cells, ATII, hepatocytes, and fibroblasts. The contribu-
tion of non-phagocytic cells to Francisella virulence was revealed 
by a recent study using a ∆pyrF SchuS4 mutant. Although this 
mutant grew less vigorously than WT bacteria in macrophages, it 
exhibited close to WT levels of growth in some non-macrophage 
cell types, and retained full virulence in the murine model of IT 
infection (Horzempa et al., 2010). Although not conclusive, this 
study suggests that Francisella growth in non-macrophage cell types 
contributes substantially to the virulence of the organism.
Alveolar epithelial cells, which form the interface between the 
outside environment and the host lung interior, are well positioned 
to interact with Francisella very early during respiratory infection. 
Similar to many other intracellular pathogens, treatment of 
infected macrophages ex vivo with IFN-γ inhibits Francisella growth. 
In quiescent murine and human macrophages, Francisella survives 
in these cells by rapidly escaping the phagosome to replicate in the 
cytosol, thereby circumventing phagosome–lysosome fusion and 
the associated bactericidal effects. LVS phagosomal escape was par-
tially diminished in IFN-γ-treated murine peritoneal exudate cells 
(PECs; Lindgren et al., 2004). Similarly, control of F. novicida growth 
by IFN-γ-activated human monocyte-derived macrophages was 
attributed to its inability to disrupt phagosome–lysosome fusion in 
the activated cells (Santic et al., 2005). These data suggest that pre-
vention of efficient escape from the phagosome is one mechanism 
by which IFN-γ inhibits Francisella intracellular growth. However, 
more recent studies examining LVS and SchuS4 growth in murine 
BMDMs and the murine macrophage-like cell line J774.1 demon-
strated that IFN-γ-activation did not disrupt phagosomal escape 
(Bonquist et al., 2008; Edwards et al., 2010). These discrepancies 
are likely to be related to the different Francisella subsp. and host 
cells used for the different studies; regardless, although disruption 
of phagosomal escape is one potential mechanism by which IFN-
γ-activation could diminish Francisella intracellular growth, it is 
certainly not the only mechanism at work.
The generation of reactive oxygen species (ROS) and RNS are 
two well-known mechanisms elicited by IFN-γ that can inhibit the 
growth of intracellular pathogens. Several studies have focused on 
defining the role of these two classic mechanisms in the control of 
Francisella growth both in vitro and in vivo. Optimal IFN-γ-induced 
inhibition of LVS growth in murine PECs required the combined 
action of Phox and iNOS, and was dependent upon the generation 
of peroxynitrite (Lindgren et al., 2005). These data are supported by 
the increased susceptibility of mice deficient for either iNOS or the 
phagocyte oxidase p47
phox to ID LVS infection as compared to WT 
mice (Lindgren et al., 2004). In contrast, killing of virulent SchuS4 
by IFN-γ-activated murine PECs was only partially dependent on 
iNOS, and correspondingly, SchuS4 was very resistant to killing by 
H2O2 and peroxynitrite compared to LVS (Lindgren et al., 2007). 
Further,  a  study  using  murine  gp91phox/iNOS  double-deficient 
BMDMs determined that control of SchuS4 growth by IFN-γ was 
independent of ROS and RNS, iron sequestration, and tryptophan 
depletion by indoleamine 2,3-dioxygenase (Edwards et al., 2010). 
Therefore, the IFN-γ-elicited bactericidal mechanism(s) involved 
in inhibition of SchuS4 growth in activated macrophages remain to 
be fully elucidated, while the less virulent LVS is more susceptible 
to the well-known bactericidal effects of ROS and RNS.
Interestingly, although LVS-infected murine macrophages ini-
tially produce pro-inflammatory cytokines in vitro, after several 
hours they begin to exhibit an “alternatively activated” phenotype – 
a condition characterized by mitigation of the pro-inflammatory 
response (including iNOS expression) and up-regulation of anti-
inflammatory cytokines such as IL-4, IL-13, and TGF-β (Shirey 
et al., 2008). Differentiation of LVS-infected macrophages into the 
alternatively activated phenotype required TLR2, IL-4, and IL-13. 
These alternatively activated macrophages are evident in the peri-
toneum upon in vivo IP LVS infection, and mice deficient for the 
IL-4 receptor α chain (used by both IL-4 and IL-13 for signaling) 
exhibited increased survival following a normally lethal IP LVS 
infection. This increased resistance was associated with prolonged Frontiers in Microbiology  |  Cellular and Infection Microbiology    February 2011  | Volume 2  | Article 26  |  12
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their critical contribution to early survival of systemic infection may 
lie in their ability to secrete cytokines and chemokines that recruit 
other important effector cells to the site of infection.
In contrast, the effect of neutrophil depletion on pulmonary 
LVS infection was much less striking than that noted for parenter-
ally infected mice, with only a minor increase in bacterial burdens 
in the livers when using a dose just above the LD50 (Conlan et al., 
2002a). Regardless, neutrophils are clearly actively recruited to 
Francisella-infected lungs: recent studies show that neutrophils 
constitute as much as 50% of the Francisella-infected cells in the 
lungs of mice 3 days after pulmonary LVS and SchuS4 infection 
(Hall et al., 2008), and depend at least partially on IL-17A for their 
early recruitment to the lungs (Lin et al., 2009; Cowley et al., 2010). 
However, excessive recruitment of neutrophils to the lung appears 
to contribute to Francisella pathogenesis: mice deficient for matrix 
metalloproteinase 9 – which generates neutrophil chemoattractants 
via cleavage of the extracellular matrix – exhibited reduced neu-
trophil numbers in the lungs after LVS pulmonary infection, and an 
associated reduction in bacterial burden that was accompanied by 
increased survival (Malik et al., 2007). Thus, the role of neutrophils 
in Francisella infection is likely to be a fine balance between aiding 
in control of infection and exacerbation of pathology.
mast cells
Mast cells are classically known for their involvement in allergic con-
ditions associated with type I hypersensitivity reactions (Geha, 2003). 
However, recent data has revealed an unexpected and intriguing role 
for mast cells and IL-4 in control of respiratory Francisella infection. 
Mast cell-deficient mice were much more susceptible to pulmonary 
LVS infection than WT mice, exhibiting diminished production of 
IL-4 in the lungs (Ketavarapu et al., 2008). Further, IL-4-deficient mice 
were slightly more susceptible to LVS pulmonary infection. In vitro, 
mast cells inhibited LVS intramacrophage growth in a manner that 
was dependent on IL-4 (Ketavarapu et al., 2008). Overall, these data 
suggest that mast cells are capable of IL-4-dependent inhibition of 
LVS growth in macrophages, a phenomenon that was associated with 
increased macrophage cellular ATP levels and co-localization of LVS 
with acidified organelles (Rodriguez et al., 2010).
nk cells
Numerous studies have shown that NK cell-deficient mice are not 
more susceptible to IN or ID LVS infection than fully immunocom-
petent mice (Lopez et al., 2004; Duckett et al., 2005; Bokhari et al., 
2008), although clear conclusions from these studies are hampered 
by the inability to fully deplete mice of NK cells in vivo. Despite 
this limitation, it is clear that NK cells are important producers of 
IFN-γ during primary LVS infection initiated via both the ID and 
IN routes. During the first 96 h after an IN LVS infection, a subset 
of CD11b+DX5+NK1.1+ cells were primarily responsible for IFN-γ 
production in the lungs and livers (Lopez et al., 2004; Bokhari et al., 
2008), while NK1.1+ cells were a large proportion of the IFN-γ 
producers in the spleens and livers of mice for the first 5–7 days 
after an ID LVS infection (De Pascalis et al., 2008). The NK1.1+ 
cell types that produce IFN-γ in response to LVS infection were 
quite heterogeneous, and could be sub-divided into populations 
phenotypically reminiscent of NK T cells and “NK DCs” (Bokhari 
et al., 2008; De Pascalis et al., 2008).
TEM micrographs showed LVS in contact with ATII cells in the 
  airways of mice 2 h after an IN infection (Gentry et al., 2007). 
In vitro cultures of primary human ATII cells stimulated with 
SchuS4 and LVS produced high levels of IL-8, MCP-1, GRO-α, and 
GM-CSF (Gentry et al., 2007). Further, these conditioned culture 
supernatants induced transmigration of PMNs and DCs through 
cultured primary human pulmonary microvasculature endothelial 
cells (HVECs), a cell type that lines blood vessels and is found in 
close juxtaposition to ATII cells in vivo (Gentry et al., 2007). Studies 
of the direct interaction of Francisella with HVECs showed that 
LVS could be internalized – but did not replicate – in these cells, 
inducing a blunted pro-inflammatory response and transmigra-
tion of PMNs with a suppressed phenotype (Forestal et al., 2003; 
Moreland et al., 2009; Bublitz et al., 2010). It is not yet known 
whether PMNs that transmigrate across the endothelial layer in 
response to chemokines produced by Francisella-infected ATII cells 
are also functionally inhibited. Regardless, it is clear that, in addi-
tion to providing an early replicative niche for Francisella, ATII cells 
have the potential to play a vital role in initiation of inflammatory 
immune responses and recruitment of key immune cells.
The mechanisms exploited by Francisella for uptake and growth 
in these non-macrophage cell types – as well as the immune mecha-
nisms that ultimately control this growth – are only beginning to 
be understood. Thus far it is clear that LVS uses host processes for 
invasion of murine ATII cells, and – similar to its growth in macro-
phages – escapes the initial phagosome to replicate in the cytoplasm 
(Craven et al., 2008). LVS infection of the human ATII cell line A549 
resulted in up-regulation of the antimicrobial β-defensin molecule 
hBD-2, but not hBD-3, the β-defensin that had the most potent 
anti-Francisella activity in a cell-free system (Han et al., 2008). 
Therefore, Francisella avoids eliciting detrimental antimicrobial 
mechanisms in resting ATII cells. However, the combined action 
of recombinant IFN-γ and IL-17A limited LVS growth in a murine 
ATII cell line in vitro (Cowley et al., 2010), and thus ATII cells can 
be activated to produce antimicrobial activity against Francisella.
neutropHIls
Another important cell type that responds early to Francisella infec-
tion is the neutrophil. Neutrophils are key innate immune cells 
that use toxic ROS, cationic peptides, and degradative enzymes to 
kill ingested pathogens. In particular, the multicomponent enzyme 
NADPH oxidase, which catalyzes the conversion of molecular oxy-
gen to superoxide anions, is a primary antimicrobial weapon in the 
neutrophil arsenal. Interestingly, although LVS and SchuS4 were 
readily phagocytosed by human neutrophils in vitro, they inhibited 
NADPH oxidase assembly and the associated production of ROS 
(McCaffrey and Allen, 2006; McCaffrey et al., 2010). Further, instead 
of being killed by neutrophils, Francisella escaped from the phago-
some and persisted in the neutrophil cytosol (McCaffrey and Allen, 
2006). Thus, instead of killing Francisella, neutrophils appear to pro-
vide a safe – if not replicative – niche for the organism. Nonetheless, 
in mice the in vivo importance of neutrophils in defense against 
systemic Francisella infection is clear: neutrophil-depleted mice are 
highly susceptible to otherwise sublethal parenteral LVS infections, 
succumbing quickly to an overwhelming disseminated infection 
(Sjostedt et al., 1994; Elkins et al., 1996; Conlan et al., 2002a). The 
inability of neutrophils to kill intracellular Francisella suggests that www.frontiersin.org  February 2011  | Volume 2  | Article 26  |  13
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although transfer of anti-LVS or anti-Francisella LPS antibodies 
conferred partial protection against LVS and the less virulent Type 
B Francisella challenges (Fortier et al., 1991; Fulop et al., 1995, 2001; 
Conlan et al., 2002b; Stenmark et al., 2003; Kirimanjeswara et al., 
2007; Lavine et al., 2007). Similarly, efforts to stimulate protective 
immunity in mice through vaccination with Francisella LPS or 
its protein-conjugated derivatives have only met with success fol-
lowing challenge with LVS or the less virulent Type B Francisella 
(Fulop et al., 1995; Conlan et al., 2002b, 2003; Kieffer et al., 2003; 
Cole et al., 2009).
Although  administration  of  inactivated  preparations  of 
Francisella or its components have historically been unable to confer 
protective immunity to virulent Francisella challenge, recent studies 
have challenged this dogma; further, some of these strategies are 
antibody-dependent. Vaccination with inactivated Francisella prep-
arations augmented by co-administration with immunostimula-
tory compounds can induce antibody-dependent protection against 
challenge with the less virulent LVS. Mice given an IN vaccination of 
killed LVS and IL-12 survived a subsequent lethal IN LVS challenge 
in an IgA-dependent manner (Baron et al., 2007). Similarly, mice 
administered heat-killed LVS IP alongside an IL-12 expressing viral 
vector survived a high dose lethal IP LVS challenge in a manner that 
was mediated by antibodies (Lavine et al., 2007). The ability of IL-12 
administration to augment humoral immunity and protect against 
virulent Francisella challenge remains to be explored. Further, mice 
vaccinated several times IP with Francisella outer membrane pro-
teins or ethanol-inactivated LVS were significantly protected against 
subsequent IN Type A F. tularensis challenge (∼40–50% survival; 
Huntley et al., 2008). Intramuscular immunization of mice with 
killed LVS in conjunction with immunostimulatory complexes 
(ISCOMs) admixed with CpG protected 40% of mice against a 
low dose SC challenge with SchuS4 (Eyles et al., 2008). Further, 
intranasal immunization of mice with inactivated LVS and the 
mucosal adjuvant cholera toxin B subunit resulted in substantial 
protection against lethal IN LVS challenge, and partial protection 
against IN SchuS4 challenge (Bitsaktsis et al., 2009). However, in 
this case the presence of a mucosal adjuvant augmented Th1-type 
responses, such that the protection mediated against LVS challenge 
was fully operative in BKO mice; thus, the observed protection was 
not actually mediated by B cells or antibodies. Overall, it appears 
that antibody-mediated immune responses generated by immuni-
zation with live or killed LVS or antigenic Francisella preparations 
are, at best, partially protective against virulent strains of Francisella, 
and that T cell functions are necessary to achieve optimal pro-
tection. Interestingly, however, antisera from mice immunized IN 
with virulent SchuS4 and subsequently rescued by levofloxacin 
treatment was able to protect ∼90% of naive mice against a lethal 
SchuS4 IN challenge (Klimpel et al., 2008).
A recent study reveals an interesting mechanism by which viru-
lent Francisella may evade the protective effects of anti-Francisella 
antibodies. The highly virulent Type A strain SchuS4 – but not 
LVS – can directly bind plasmin, a host serine protease that degrades 
opsonizing antibodies, thus inhibiting antibody-mediated uptake of 
SchuS4 by macrophages (Crane et al., 2009). Importantly, antibody-
opsonized SchuS4 elicited increased production of TNF-α and IL-6 
from macrophages, an effect that was reduced by the addition of plas-
min. Thus, the ability of SchuS4 to bind plasmin likely contributes to 
Further studies investigating the role of NK cell production of 
IFN-γ in Francisella infection have revealed some of its downstream 
impacts. For example, human monocyte production of IL-23 in 
responses to Francisella infection induced NK cells to produce 
IFN-γ; this IFN-γ subsequently up-regulated monocyte produc-
tion of IL-23 and IL-12p70, establishing NK cells at the center of 
a positive feedback loop for IL-23 and IFN-γ production (Butchar 
et al., 2007, 2008b). In addition, NK cell production of IFN-γ was 
critical for hepatic granuloma formation during IN LVS infection; 
depletion of NK cells – although not lethal to the mice – resulted in 
“leaky” granulomas that poorly contained the infection (Bokhari 
et al., 2008).
Overall, although NK1.1
+ cells clearly respond vigorously to early 
Francisella infection, much of their contribution identified thus 
far relates to IFN-γ-production; the role of the lytic activities of 
NK cells has not been studied directly. Since NK1.1+ cells are not 
the only innate immune cells capable of producing IFN-γ during 
these early critical time points (other cell types identified included 
DCs, PMNs, and macrophages; De Pascalis et al., 2008), it is likely 
that compensation by these other cells explains the dispensability 
of NK cells during survival of primary sublethal LVS infection. 
Indeed, mice depleted of NK cells during primary IN LVS infection 
exhibited only a 50% decrease in serum IFN-γ as compared to their 
WT counterparts (Bokhari et al., 2008).
elements of tHe adaptIve Immune response
Elucidation of the mechanisms involved in protection against intra-
cellular pathogens is critical for successful vaccine development. 
Adaptive immune responses typically develop over a longer time 
frame than that of innate immunity, first requiring activation and 
clonal expansion of antigen-specific B and T cells. The resulting 
memory T and B cells respond rapidly to a second exposure to their 
cognate antigen, thus forming the basis of vaccine-induced immu-
nity. For many intracellular pathogens, cellular immune responses 
have received the greatest attention; organisms are sequestered 
within cells and relatively inaccessible to antibodies, and as dis-
cussed above, serum antibody levels often do not correlate with 
protection. Thus T cell mechanisms including cytokine production 
and cytotoxicity are logical candidates for effecting pathogen eradi-
cation. However, recent data demonstrating significant extracellular 
phases for Francisella in vivo (Forestal et al., 2007; Yu et al., 2008), as 
well as a clear contribution of B cell-mediated functions to protec-
tion against secondary infections with Francisella strains of lower 
virulence, are leading to a new appreciation for how a combination 
of both B and T cell responses contribute to protective immunity 
against Francisella (for an overview, refer to Figure 1).
b lympHocytes and antIbodIes
As discussed above, while specific antibodies are clearly made dur-
ing Francisella infection and following vaccination, their contribu-
tion to protection may be relatively limited, at least in isolation. 
Murine studies have used both passive transfer of immune sera and/
or purified antibodies, as well as genetically deficient mice, to elu-
cidate the role of B cells and antibodies in resistance to Francisella 
infection. Older studies demonstrated that immune serum trans-
fer to naive animals does not confer protection against the highly 
virulent Type A Francisella strains (Thorpe and Marcus, 1967), Frontiers in Microbiology  |  Cellular and Infection Microbiology    February 2011  | Volume 2  | Article 26  |  14
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t lympHocytes: t cell subpopulatIons
Although B cells and their products have significant roles in pro-
tective immunity to Francisella, optimal protection to Francisella 
infection clearly requires T cell-mediated immunity. Mice defi-
cient in T cells (such as nu/nu or α/β TCR-deficient mice) initially 
control a primary sublethal parenteral LVS infection, but the mice 
maintain high bacterial organ burdens and ultimately succumb 
after approximately a month. Both CD4+ and CD8+ T cells are suffi-
cient to resolve this infection, as mice depleted of either population 
individually clear the bacteria from the tissues. In contrast, mice 
simultaneously depleted of both CD4+ and CD8+ T cells survive – 
but do not clear – LVS infection, instead developing a long-term 
chronic infection for many months that is characterized by steady 
levels of bacteria in the organs of the reticuloendothelial system. 
Control of LVS infection in these depleted mice has been attrib-
uted to an unusual CD4−CD8−NK1.1−TCRαβ+Thy1.2+ “DN” T cell 
population. Enriched populations of these cells potently control 
LVS intramacrophage growth in vitro (Cowley et al., 2005). Thus, 
a variety of T cells contribute to control of primary parenteral LVS 
infection in mice, although only CD4+ and CD8+ αβ T cells have 
the ability to fully resolve the infection.
The role of T cells in the control and clearance of murine pri-
mary sublethal respiratory LVS infection is considerably less well 
studied than parenteral infection. Mice simultaneously depleted 
of CD4+ and CD8+ T cells and infected with LVS IN also develop a 
long-term chronic infection, indicating that one or both of these 
T cell subsets are necessary for clearance of pulmonary infections 
(Cowley et al., 2010). However, the requirement for the individual 
T cell subsets, or αβ TCR+ T cells as a group, has not been system-
atically studied in pulmonary LVS infection. Since fully immu-
nocompetent mice die following both parenteral and respiratory 
primary infections with virulent Francisella, it is not surprising 
that infected mice deficient in T cells die at the same time (Chen 
et al., 2004; Wu et al., 2005). Interestingly, lethal murine pulmonary 
infection with virulent type A F. tularensis has been shown to result 
in thymic atrophy and loss of CD4+CD8+ thymocytes (Chen et al., 
2005a), whereas mice given a lethal pulmonary F. novicida infec-
tion exhibited a profound depletion of αβ T cells in their lungs that 
was associated with apoptosis (Sharma et al., 2009). Overall, these 
data suggest that primary lethal pulmonary Francisella infections 
share the ability to undermine the development and/or function 
of T cell-mediated immune responses.
t lympHocytes: effector mecHanIsms
Efforts to determine the T cell mechanisms that contribute to 
defense against Francisella infection have revealed a small number 
of key cytokines that are produced by responding T cells. CD4+, 
CD8+, and DN T cells in the lungs of mice given a primary sublethal 
LVS pulmonary infection produce IFN-γ and IL-17A (Woolard 
et al., 2008; Cowley et al., 2010). Correspondingly, mice deficient in 
either IFN-γ or IL-17A exhibit increased susceptibility to primary 
LVS pulmonary and ID infections (Lin et al., 2009; Cowley et al., 
2010; Markel et al., 2010). However, since both cytokines are also 
produced by innate immune cells (see above), it is difficult to deter-
mine the relative importance of production of these factors by T 
cells versus that of other cell types during primary in vivo infection. 
Greater success on this front has been achieved through the use of 
its capacity to evade the host antibodies response. Further, the in vivo 
protective effects provided by adoptively transferred immune serum 
against IN LVS challenge were dependent upon the Fcγ receptor and 
alveolar macrophages, indicating a role for opsonophagocytosis in 
antibody-mediated protection to LVS (Kirimanjeswara et al., 2007). 
Control of LVS growth by IFN-γ-treated alveolar macrophages was 
significantly greater when the bacteria had been serum opsonized 
prior to uptake (Kirimanjeswara et al., 2007). Since LVS does not 
bind plasmin, it is subject to opsonophagocytosis by macrophages 
that are stimulated to increase their production of pro-inflammatory 
mediators and control intracellular growth more potently. These 
phenomena may at least partially explain the aforementioned abil-
ity of adoptively transferred sera to protect against LVS, but not 
SchuS4, challenges.
A  novel  role  for “innate  immune  B  cells”  in  immunity  to 
Francisella has emerged in the last several years. Called B-1 lym-
phocytes, these cells are primarily located in the pleural cavity, 
intestinal mucosa, and the spleen of mice, and rapidly produce 
antibodies  against  T-independent  antigens.  In  the  Francisella 
murine infection model, these cells mediate a very rapid antibody 
response within 2–3 days of LVS or Ft-LPS vaccination. The B-1a B 
cell response and resulting antibody secretion provides substantial 
protection against moderate lethal LVS challenges administered IP, 
and was not dependent on the presence of T cells (Dreisbach et al., 
2000; Cole et al., 2009). In the Ft-LPS-vaccinated mice, B1a cells 
proliferated in the spleen, and differentiated into plasma cells that 
produced Ft-LPS-specific antibodies that were detectable in the sera 
by days 3–4 after immunization. This protection did not depend on 
TLR4 and was not elicited by LVS lipid A, indicating that the epitope 
recognized by B1a cells is LVS O antigen. Whether these rapid B1a 
protective responses provide immunity to Francisella challenge via 
other routes of infection remains to be determined. Nonetheless, 
the discovery that the resultant anti-Ft-LPS antibodies were detect-
able at low levels in the serum for months after immunization 
suggests that they have the capacity to contribute to longer-term 
immune responses, in addition to rapid immunity.
It is important to note that the contributions of B cells to pri-
mary and secondary Francisella infections may be quite different. 
B cell-deficient mice (BKO) given a primary ID LVS infection con-
trolled bacterial growth with kinetics similar to WT mice with a 
minimal impact on overall susceptibility, and similarly, BKO mice 
administered a primary low dose aerosol LVS infection also readily 
survived (Elkins et al., 1999; Chen et al., 2004). In contrast, LVS-
vaccinated BKO mice were significantly more susceptible than their 
WT counterparts to IP LVS secondary challenge, in a manner that 
could be readily rescued by transfer of immune splenic B cells but 
not immune sera (Elkins et al., 1999). Thus, in addition to revealing 
a more significant role for B cells in secondary as compared to pri-
mary infection, these results further suggest that part but not all of 
the contribution of B cells to protective immunity during secondary 
LVS challenge is antibody-mediated. The role of other functions 
of B cells, such as production of cytokines and chemokines and 
antigen presentation, remains to be fully explored. Interestingly, 
recent evidence indicates that Francisella can grow inside B cells, 
ultimately inducing apoptosis of the infected cells (Krocova et al., 
2008). Thus the potential for Francisella to subvert B cell functions 
from within remains an interesting avenue for future research.www.frontiersin.org  February 2011  | Volume 2  | Article 26  |  15
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an in vitro co-culture system, which directly measures the ability of 
LVS-immune T cells to control LVS intramacrophage growth. Using 
this system, it is apparent that IFN-γ and TNF-α contribute to the 
ability of all three T cell subsets to control LVS intramacrophage 
growth. However, the different T cell subsets utilize these two fac-
tors differentially: LVS-immune CD4+ T cells exhibited the greatest 
reliance on IFN-γ to control LVS growth, while LVS-immune CD8+ 
and DN T cells displayed a greater degree of IFN-γ-independence 
(Cowley and Elkins, 2003). In contrast, LVS-immune CD4+ T cells 
did not require TNF-α to control LVS intramacrophage growth, 
while CD8+ T cells were almost completely reliant on TNF-α pro-
duction (Cowley et al., 2007). Further, LVS-immune CD8+ T cells 
were capable of utilizing the membrane-bound form of TNF-α, in 
the absence of soluble TNF-α, to execute full control of LVS growth 
in vitro (Cowley et al., 2007).
Secondary immune responses to LVS vaccination in mice have 
typically been studied by administering either IP, IV, or pulmonary 
Francisella challenges at doses that are lethal for a naive mouse. For 
secondary LVS IP challenges, all three αβ T cell subsets – CD4+, 
CD8+, and DN T cells – are sufficient individually for survival 
and clearance of an LVS infection. However, mice with only DN 
T cells (i.e., simultaneously depleted of both CD4+ and CD8+ T cells) 
eradicated the infection more slowly. In contrast, full resistance to 
virulent F. tularensis pulmonary secondary challenges of vaccinated 
mice requires both CD4+ and CD8+ T cells, as depletion of either T 
cell subset significantly reduces survival (Conlan et al., 2005; Wu 
et al., 2005; Bakshi et al., 2008).
Elucidation of immune T cell effector mechanisms that pro-
mote survival of secondary challenges remains an ongoing area 
of active investigation. Such information is likely to be critical for 
derivation of protective correlates of immunity. Mice administered 
neutralizing anti-TNF-α antibodies during lethal IV LVS second-
ary challenge were highly susceptible to the infection, exhibiting 
bacterial burdens that exceeded those of mice similarly treated with 
anti-IFN-γ antibodies (Sjostedt et al., 1996). However, mice geneti-
cally engineered to produce only the membrane-bound form of 
TNF-α (and not the soluble form), were resistant to a high lethal 
secondary IP LVS challenge and generated similar numbers of 
CD44hi-responding T cells in their spleens. These data suggest 
that membrane TNF-α is sufficient for the generation of activated 
responding memory T cells (Cowley et al., 2007). In contrast, mice 
treated with anti-IFN-γ Abs at the time of secondary IP LVS chal-
lenges were only able to survive the lowest challenge doses, and 
T cells harvested from vaccinated IFN-γ-deficient mice failed to 
control LVS intramacrophage growth in vitro, indicating that IFN-γ 
is required for successful priming of LVS-immune T cells (Elkins 
et al., 2010). In addition to clear roles for IFN-γ and TNF-α, one 
recent study found that vaccine efficacy against SchuS4 challenge 
best correlated with pulmonary levels of IL-17 (Shen et al., 2010). 
Further, antibody neutralization of IL-17A during in vivo secondary 
challenge slightly enhanced SchuS4 growth in mouse lungs, indi-
cating that IL-17A may participate in vaccine-induced immunity 
to Francisella (Shen et al., 2010).
Classic cytotoxic T cell mechanisms do not appear to play a sig-
nificant role in survival of primary or secondary LVS infections in 
mice, and similarly do not contribute to the ability of LVS-immune 
murine T cells to control LVS intramacrophage growth in vitro 
(Cowley, manuscript in preparation). However, the recent finding 
that Francisella is susceptible to killing by granulysin, a lytic antimi-
crobial peptide component of human – but not mouse – cytolytic 
granules, suggests that granule cytotoxicity may be an effective part 
of the human T and NK cell arsenal that cannot be assessed in the 
mouse model (Endsley et al., 2009).
The study of T cell responses during Francisella infection has 
been hampered by a paucity of information on the precise epitopes 
recognized by antigen-specific T cells, and a corresponding lack of 
tools such as tetramers to probe T cell biology. Efforts to identify 
protein epitopes recognized by T cells during Francisella infection 
have only recently begun to come to fruition. To date, T cell hybrid-
omas, bioinformatics, proteomics, and “immunoinformatics” have 
been applied to identify several Francisella T cell epitopes in both 
mice and humans (McMurry et al., 2007; Valentino and Frelinger, 
2009; Valentino et al., 2009; Yu et al., 2010). One murine CD4
+ T cell 
epitope has been identified as amino acids 86–99 of the lipoprotein 
Tul4 (Valentino et al., 2009). Constituting as much as 20% of the 
responding splenic CD4+ T cells at the height of an ID LVS infec-
tion, this epitope appears to be immunodominant in C57Bl/6 mice 
(Valentino et al., 2009). Other murine studies have identified the 
LVS proteins GroEl, KatG, and bacterioferritin (Bfr) as immunos-
timulatory during in vitro recall assays with splenocytes harvested 
from LVS-vaccinated BALB/c mice, although the exact epitopes 
present in these proteins have yet to be identified (Lee et al., 2006). 
The identification of human epitopes has been approached largely 
through bioinformatics analyses to select candidate promiscuous 
or supertype CD4+ and CD8+ epitopes in the SchuS4 genome; this 
effort yielded a large number of candidate epitopes that induced 
low levels of IFN-γ production by PBMCs from former tularemia 
patients (McMurry et al., 2007). Immunization with a pool of 13 
of these epitopes provided some protective immunity against a two 
or five LD50 IT LVS challenge in HLA class II (DRB1*0401) trans-
genic mice (Gregory et al., 2009), but this effort utilized a difficult 
vaccination regimen. Further studies to identify alternate vehicles 
or routes of vaccination will no doubt be necessary to develop a 
peptide-based vaccination approach that is feasible for humans.
Despite apparently productive interactions between T cells and 
Francisella-infected macrophages in vitro, infected macrophages 
also have the capacity to directly inhibit T cell responses in vitro. 
PGE2 production by BMDMs infected with a high multiplicity 
of infection of LVS inhibited proliferation of T cell hybridomas 
specific for SIINFEKL and hen egg lysozyme antigens, skewing the 
T cell responses from IL-2 to IL-5 production (Woolard et al., 2007). 
In addition, macrophage production of a PGE2-dependent factor 
modulated antigen presentation by LVS-infected macrophages via 
ubiquitinization and degradation of macrophage MHC class II 
molecules (Wilson et al., 2009). Finally, F. novicida-infected mac-
rophages inhibited expression of the IFN-γ receptor and dimin-
ished the ability of ovalbumin-specific T cells to produce IL-2 in 
response to their cognate antigen (Roth et al., 2009). The in vivo 
consequences of these phenomena remain to be fully explored, 
although inhibition of the PGE-2-producing enzyme cyclooxygen-
ase in mice during LVS pulmonary infection increased the number 
of IFN-γ-producing T cells and decreased the bacterial burden in 
the lungs. Thus lung PGE2 production may have a significant 
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  infection, and only a small but detectable increase in susceptibility 
was evident upon secondary IP challenge (Yee et al., 1996; Markel 
et al., 2010). However, studies using the primary sublethal pul-
monary infection model revealed that these cells respond in the 
lungs of LVS-infected mice by producing IL-17A (Lin et al., 2009; 
Markel et al., 2010). Thus, overall it appears that any responses 
provided by γδ T cells in the murine model are not essential for 
survival of LVS infection.
conclusIons and perspectIves
In the last 5 years, abundant new findings have added to an already 
rich literature regarding Francisella pathogenesis and immunity. Of 
necessity, some of it has been more descriptive than hypothesis-
driven, in reporting new genetic systems, results of genomic mining, 
advances in establishing and characterizing novel animal models, 
and in cataloging responding host cell types and mediators. But 
the tools developed are now poised to have payoffs not only for 
understanding of human infection with Francisella per se, but for 
insights into the biology of intracellular pathogens in general. As 
an experimental model, Francisella is unique in establishing pro-
ductive infection in a huge variety of insects and mammals by 
many routes. Between this convenient biology and the plethora 
of experimental options now available, the field is well poised to 
perform detailed mechanistic studies. To do so, immunologists, 
long biased toward studies in mice, may need to make room in their 
thinking and their animal colonies for species with advantages in 
modeling human infection, such as rats. The Francisella models 
seem to be particularly attractive for tackling some of the current 
themes regarding immunity to pathogens: comparing similarities 
and differences in systemic or mucosal immunity; understanding 
the tension between pathogen-induced immunosuppression and 
host immunoresponsiveness; appreciating the ongoing interplay 
between rapid innate reactions and later specific immunity; and 
getting past a tendency to think of adaptive immune responses as 
either antibody-centric or T cell dominated, when instead both may 
complement, augment, and regulate each other. Collectively, we 
expect studies on immunity to Francisella to continue to be excit-
ing, novel, and perhaps pivotal in achieving a critical public health 
goal: the search for predictive correlates of protective immunity to 
intracellular pathogens.
Similar to murine Francisella infections and as discussed above, 
human CD4+ and CD8+ T cell responses have been demonstrated. 
PBMCs from LVS vaccines and naturally infected tularemia patients 
produce typical Th1-type cytokines such as IL-2, IFN-γ, and TNF-α 
upon ex vivo re-stimulation with LVS or its antigens (Karttunen 
et al., 1991; Surcel et al., 1991; Salerno-Goncalves et al., 2009). 
Further, memory CD4+ and CD8+ T cells in re-stimulated PBMCs 
from LVS-vaccinated volunteers also produce the Th17 cytokines 
IL-17 and IL-22 (Paranavitana et al., 2010). One recent study further 
investigated the phenotype of LVS-induced recall responses in the 
PBMCs of tularemia patients and LVS vaccines, revealing that CD4+ 
and CD8+ T cell responders (as defined by IFN-γ-production and/
or proliferation) largely exhibited an effector memory phenotype, 
and expressed cell surface markers that were indicative of cytolytic 
potential and the ability to home to both mucosal and non-mucosal 
sites (Salerno-Goncalves et al., 2009). These effector memory cells 
were long-lived and in some cases detected greater than 25 years 
after primary pneumonic tularemia.
In addition to CD4+ and CD8+ T cell responses, it is interesting 
to note that γ/δ T cells respond vigorously to Francisella infection 
in humans. The Vγ9/Vδ2 γδ T cell subset is known for its ability 
to specifically respond to pathogen-produced non-peptidic phos-
phoesters known collectively as “phosphoantigens.” In tularemia 
patients, the Vγ9/Vδ2 subset expanded to constitute as much as 
30.5% of all CD3+ cells in human peripheral blood within the 
first 7 days after the onset of symptoms (Poquet et al., 1998). 
These cells remained elevated for at least a month, and persisted 
in some individuals for as long as a year after infection (Kroca 
et al., 2000). Acellular extracts from a variety of Francisella strains, 
including LVS, contained phosphoantigens that activated Vγ9/
Vδ2 T cell expansion and effector functions in human PBMCs. 
Curiously, despite the existence of activating phosphoantigens 
in LVS extracts, LVS vaccines do not exhibit the same Vγ9/Vδ2 
T cell subset expansion as tularemia patients. Since mice do not 
express a γδ T cell receptor that is homologous to Vγ9/Vδ2, it 
has not been possible to further explore this phenomenon in 
the murine model of infection. To date, only a small number of 
studies have addressed the role of γδ T cells in murine tularemia. 
Mice deficient for the γδ T cell receptor did not exhibit nota-
ble increased susceptibility to primary sublethal ID or IN LVS www.frontiersin.org  February 2011  | Volume 2  | Article 26  |  17
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